Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Cash from Financing Activities (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Cash from Financing Activities for 4 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 16.85% to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.0 million, a 15.21% decrease, with the full-year FY2024 number at $7.1 million, up 8.94% from a year prior.
  • Cash from Financing Activities was $4.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $1.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $6.0 million in Q3 2023 to a low of -$68629.0 in Q4 2022.
  • A 4-year average of $1.9 million and a median of $1.0 million in 2023 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 943.54% in 2024; the steepest drop was 100.27% in 2024.
  • 60 Degrees Pharmaceuticals' Cash from Financing Activities stood at -$68629.0 in 2022, then skyrocketed by 8800.56% to $6.0 million in 2023, then crashed by 99.98% to $973.0 in 2024, then surged by 440000.51% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Cash from Financing Activities are $4.3 million (Q3 2025), $1.7 million (Q1 2025), and $973.0 (Q4 2024).